Fenbendazole improves pathological and functional recovery following traumatic spinal cord injury

Neuroscience

Volumn 256, Issue , 2014, Pages 163-169

  Yu, C G ^a   Singh, R ^a   Crowdus, C ^a   Raza, K ^a   Kincer, J ^a   Geddes, J W ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Locomotor function; Pathogenic autoantibody; Traumatic injury

Indexed keywords

ANTHELMINTIC AGENT; AUTOANTIBODY; BENZIMADOLE; FENBENDAZOLE; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; CD45 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; AXONAL INJURY; B LYMPHOCYTE; C57BL 6 MOUSE; CONTROLLED STUDY; CONTUSION; CONVALESCENCE; DRUG APPROVAL; DRUG MECHANISM; FEMALE; FOOD AND DRUG ADMINISTRATION; IMMUNE RESPONSE; IMMUNOREACTIVITY; LOCOMOTION; LYMPHOCYTE PROLIFERATION; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD FUNCTION; SPINAL CORD INJURY; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECTS; INJURY SCALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPINAL CORD; SPINAL CORD INJURIES; TIME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD45; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FENBENDAZOLE; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; RECOVERY OF FUNCTION; SPINAL CORD; SPINAL CORD INJURIES; TIME FACTORS; TRAUMA SEVERITY INDICES;

EID: 84888056829     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.10.039     Document Type: Article

References (41)

1. Ankeny D.P., Popovich P.G. B cells and autoantibodies: complex roles in CNS injury. Trends Immunol 2010, 31:332-338.
2. Ankeny D.P., Guan Z., Popovich P.G. B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J Clin Invest 2009, 119:2990-2999.
3. Basso D.M., Fisher L.C., Anderson A.J., Jakeman L.B., McTigue D.M., Popovich P.G. Basso mouse scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma 2006, 23:635-659.
4. Bisler S., Schleicher A., Gass P., Stehle J.H., Zilles K., Staiger J.F. Expression of c-Fos, ICER, Krox-24 and JunB in the whisker-to-barrel pathway of rats: time course of induction upon whisker stimulation by tactile exploration of an enriched environment. J Chem Neuroanat 2002, 23:187-198.
5. Cabaj W., Stankiewicz M., Jonas W.E., Moore L.G. Fenbendazole and its effect on the immune system of the sheep. NZ Vet J 1994, 42:216-220.
6. Cai Y., Zhou J., Webb D.C. Treatment of mice with fenbendazole attenuates allergic airways inflammation and Th2 cytokine production in a model of asthma. Immunol Cell Biol 2009, 87:623-629.
7. Campbell W.C. Benzimidazoles: veterinary uses. Parasitol Today 1990, 6:130-133.
8. Carvey P.M., Hendey B., Monahan A.J. The blood-brain barrier in neurodegenerative disease: a rhetorical perspective. J Neurochem 2009, 111:291-314.
9. Colburn R.W., DeLeo J.A. The effect of perineural colchicine on nerve injury-induced spinal glial activation and neuropathic pain behavior. Brain Res Bull 1999, 49:419-427.
10. Cray C., Villar D., Zaias J., Altman N.H. Effects of fenbendazole on routine immune response parameters of BALB/c mice. JAALAS 2008, 47:32-36.
11. Crittenden D.B., Lehmann R.A., Schneck L., Keenan R.T., Shah B., Greenberg J.D., Cronstein B.N., Sedlis S.P., Pillinger M.H. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol 2012, 39:1458-1464.
12. Cumino A.C., Elissondo M.C., Denegri G.M. Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int 2009, 58:270-277.
13. Fehlings M.G., Nguyen D.H. Immunoglobulin G: a potential treatment to attenuate neuroinflammation following spinal cord injury. J Clin Immunol 2010, 30(Suppl 1):S109-S112.
14. Friedman P.A., Platzer E.G. Interaction of anthelmintic benzimidazoles and benzimidazole derivatives with bovine brain tubulin. Biochim Biophys Acta 1978, 544:605-614.
15. Fuchs R. Evaluation of certain veterinary drug residues in food. WHO technical report series 1993, Vol. 832. World Health Organziation, Geneva.
16. Gadad B.S., Daher J.P., Hutchinson E.K., Brayton C.F., Dawson T.M., Pletnikov M.V., Watson J. Effect of fenbendazole on three behavioral tests in male C57BL/6N mice. JAALAS 2010, 49:821-825.
17. Giulian D., Robertson C. Inhibition of mononuclear phagocytes reduces ischemic injury in the spinal cord. Ann Neurol 1990, 27:33-42.
18. Hayes K.C., Hull T.C., Delaney G.A., Potter P.J., Sequeira K.A., Campbell K., Popovich P.G. Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J Neurotrauma 2002, 19:753-761.
19. Hellal F., Hurtado A., Ruschel J., Flynn K.C., Laskowski C.J., Umlauf M., Kapitein L.C., Strikis D., Lemmon V., Bixby J., Hoogenraad C.C., Bradke F. Microtubule stabilization reduces scarring and causes axon regeneration after spinal cord injury. Science 2011, 331:928-931.
20. Hoane M.R., Kaplan S.A., Ellis A.L. The effects of nicotinamide on apoptosis and blood-brain barrier breakdown following traumatic brain injury. Brain Res 2006, 1125:185-193.
21. Jasra N., Sanyal S.N., Khera S. Effect of thiabendazole and fenbendazole on glucose uptake and carbohydrate metabolism in Trichuris globulosa. Vet Parasitol 1990, 35:201-209.
22. Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990, 6:112-115.
23. Landin A.M., Frasca D., Zaias J., Van der Put E., Riley R.L., Altman N.H., Blomberg B.B. Effects of fenbendazole on the murine humoral immune system. JAALAS 2009, 48:251-257.
24. Lucin K.M., Sanders V.M., Jones T.B., Malarkey W.B., Popovich P.G. Impaired antibody synthesis after spinal cord injury is level dependent and is due to sympathetic nervous system dysregulation. Exp Neurol 2007, 207:75-84.
25. Lucin K.M., Sanders V.M., Popovich P.G. Stress hormones collaborate to induce lymphocyte apoptosis after high level spinal cord injury. J Neurochem 2009, 110:1409-1421.
26. Magnuson D.S., Lovett R., Coffee C., Gray R., Han Y., Zhang Y.P., Burke D.A. Functional consequences of lumbar spinal cord contusion injuries in the adult rat. J Neurotrauma 2005, 22:529-543.
27. Onifer S.M., Zhang Y.P., Burke D.A., Brooks D.L., Decker J.A., McClure N.J., Floyd A.R., Hall J., Proffitt B.L., Shields C.B., Magnuson D.S. Adult rat forelimb dysfunction after dorsal cervical spinal cord injury. Exp Neurol 2005, 192:25-38.
28. Rabchevsky A.G., Fugaccia I., Sullivan P.G., Scheff S.W. Cyclosporin A treatment following spinal cord injury to the rat: behavioral effects and stereological assessment of tissue sparing. J Neurotrauma 2001, 18:513-522.
29. Ramp A.A., Hall C., Orian J.M. Strain-related effects of fenbendazole treatment on murine experimental autoimmune encephalomyelitis. Lab Anim 2010, 44:271-273.
30. Readnower R.D., Chavko M., Adeeb S., Conroy M.D., Pauly J.R., McCarron R.M., Sullivan P.G. Increase in blood-brain barrier permeability, oxidative stress, and activated microglia in a rat model of blast-induced traumatic brain injury. J Neurosci Res 2010, 88:3530-3539.
31. Reiss C.S., Herrman J.M., Hopkins R.E. Effect of anthelminthic treatment on the immune response of mice. Lab Anim Sci 1987, 37:773-775.
32. Rite I., Machado A., Cano J., Venero J.L. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 2007, 101:1567-1582.
33. Saltzman J.W., Battaglino R.A., Salles L., Jha P., Sudhakar S., Garshick E., Stott H.L., Zafonte R., Morse L.R. B-cell maturation antigen, a proliferation-inducing ligand, and B-cell activating factor are candidate mediators of spinal cord injury-induced autoimmunity. J Neurotrauma 2013, 30:434-440.
34. Scheff S.W., Rabchevsky A.G., Fugaccia I., Main J.A., Lumpp J.E. Experimental modeling of spinal cord injury: characterization of a force-defined injury device. J Neurotrauma 2003, 20:179-193.
35. Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25years of image analysis. Nat Methods 2012, 9:671-675.
36. Sharma H.S. Pathophysiology of blood-spinal cord barrier in traumatic injury and repair. Curr Pharm Des 2005, 11:1353-1389.
37. Spagnuolo P.A., Hu J., Hurren R., Wang X., Gronda M., Sukhai M.A., Di Meo A., Boss J., Ashali I., Beheshti Zavareh R., Fine N., Simpson C.D., Sharmeen S., Rottapel R., Schimmer A.D. The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood 2010, 115:4824-4833.
38. Yu C.G., Geddes J.W. Sustained calpain inhibition improves locomotor function and tissue sparing following contusive spinal cord injury. Neurochem Res 2007, 32:2046-2053.
39. Yu C.G., Yezierski R.P., Joshi A., Raza K., Li Y., Geddes J.W. Involvement of ERK2 in traumatic spinal cord injury. J Neurochem 2010, 113:131-142.
40. Zhang Y., Popovich P. Roles of autoantibodies in central nervous system injury. Discov Med 2011, 11:395-402.
41. Zhang Y., Guan Z., Reader B., Shawler T., Mandrekar-Colucci S., Huang K., Weil Z., Bratasz A., Wells J., Powell N.D., Sheridan J.F., Whitacre C.C., Rabchevsky A.G., Nash M.S., Popovich P.G. Autonomic dysreflexia causes chronic immune suppression after spinal cord injury. J Neurosci 2013, 33:12970-12981.